• 1
    Lowenberg B,Downing JR,Burnett A. Acute myeloid leukemia. N Engl J Med. 1999; 341: 10511062.
  • 2
    Aul C,Giagounidis A,Germing U, et al. Evaluating the prognosis of patients with myelodysplastic syndromes. Ann Hematol. 2002; 81: 485497.
  • 3
    Menzin J,Lang K,Earle CC, et al. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med. 2002; 162: 15971603.
  • 4
    Behringer B,Pitako JA,Kunzmann R, et al. Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single center retrospective study. Ann Hematol. 2003; 82: 381389.
  • 5
    Goldstone AH,Burnett AK,Wheatley K, et al. Medical Research Council Adult Leukemia Working Party. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001; 98: 13021311.
  • 6
    Rowe JM. Treatment of acute myelogenous leukemia in older adults. Leukemia. 2000; 14: 480487.
  • 7
    Frohling S,Schlenk RF,Kayser S, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood. 2006; 108: 32803288.
  • 8
    Leith CP,Kopecky KJ,Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997; 89: 33233329.
  • 9
    Rossi G,Pelizzari AM,Bellotti D, et al. Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients. Leukemia. 2000; 14: 636641.
  • 10
    Taylorfsfa P,Bown N,Cuthbert G, et al. A population based study of de-novo AML to assess karyotype incidence pattern and its impact on survival by age cohorts. Ann Haematol. 2001; 80: S19.
  • 11
    Bennett JM,Catovsky D,Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-America-British Co-operative Group. Ann Intern Med. 1985; 103: 620625.
  • 12
    Bennett JM,Catovsky D,Daniel MT, et al. The French-America-British Co-operative Group: proposals for classification of the myelodysplastic syndromes. Br J Haematol. 1982; 51: 189199.
  • 13
    Mitelman F. ISCN: An International System for Human Cytogenetic Nomenclature. Basel: S. Karger; 1995.
  • 14
    Cheson BD,Bennett JM,Kantarjian H, et al. Report of an International Working Group to standardize response criteria for myelodysplastic syndromes. Blood. 2000; 96: 36713674.
  • 15
    Cheson BD,Cassileth PA,Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990; 8: 813819.
  • 16
    Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50: 163170.
  • 17
    Snedecar GW,Cochran WB. Statistical Methods. 6th ed. Ames: Iowa State University Press; 1967.
  • 18
    Cox DR. Regression models and life tables. J R Stat Soc. 1972; 34: 187220.
  • 19
    Berman E,Heller G,Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 1991; 77: 16661674.
  • 20
    Lowenberg B,Zittoun R,Kerkhofs H, et al. On the value of intensive remission-induction therapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol. 1989; 7: 12681274.
  • 21
    Tricot G,Boogaerts MA. The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes. Br J Haematol. 1986; 63: 477483.
  • 22
    Fenaux P,Morel P,Rose C, et al. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol. 1991; 77: 497501.
  • 23
    Hamblin TJ. Intensive chemotherapy in myelodysplastic syndromes. Blood Rev. 1992; 6: 215219.
  • 24
    Kern W,Haferlach T,Schoch C, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 trial. Blood. 2001; 101: 6470.
  • 25
    Byrd JC,Mrozek K,Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002; 100: 43254336.
  • 26
    Bloomfield CD,Goldman A,Hassfeld D, et al. Fourth International Workshop on Chromosomes in Leukemia 1982: clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia. Cancer Genet Cytogenet. 1984; 11: 332350.
  • 27
    Arthur DC,Berger R,Golomb HM, et al. The clinical significance of karyotype in acute myelogenous leukemia. Cancer Genet Cytogenet. 1989; 40: 203216.
  • 28
    Fenaux P,Preudhomme C,Lai JL, et al. Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases. Br J Haematol. 1989; 73: 6167.
  • 29
    Schiffer CA,Lee EJ,Tomiyasu T, et al. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood. 1989; 73: 263270.
  • 30
    Stasi R,Del Poeta G,Masi M, et al. Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia. Cancer Genet Cytogenet. 1993; 67: 2834.
  • 31
    Dastugue N,Payen C,Lafage-Pochitaloff M, et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT Group. Leukemia. 1995; 9: 14911498.
  • 32
    Bloomfield CD,Lawrence D,Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998; 58: 41734179.
  • 33
    Grimwade D,Walker H,Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998; 92: 23222333.
  • 34
    Slovak ML,Kopecky KJ,Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 2000; 96: 40754083.
  • 35
    Mrozek K,Heinonen K,Bloomfield CD. Clinical importance of cytogenetics in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001; 14: 1947.
  • 36
    Grimwade D,Walker H,Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001; 98: 13121320.
  • 37
    Keating MJ,Smith TL,Gehan FA, et al. Factors related to length of complete remission in adult acute leukemia. Cancer. 1980; 45: 20172029.
  • 38
    Norgaard JM,Olesen G,Kristensen JS, et al. Leukaemia cell drug resistance and prognostic factors in AML. Eur J Haematol. 1999; 63: 219224.
  • 39
    Jackson GH,Taylor PR. Acute myeloid leukaemia: optimising treatment in elderly patients. Drugs Aging. 2002; 19: 571581.
  • 40
    Fiegl M,Buchner T,Hiddemann W, et al. A phase I/II study of oral etoposide and idarubicin in elderly patients with high-risk acute myeloid leukemia unable to undergo intensive chemotherapy. Ann Hematol. 2005; 84: 227231.
  • 41
    Schmelz K,Sattler N,Wagner M, et al. Induction of gene expression by 5-Aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms. Leukemia. 2005; 19: 103111.
  • 42
    Ruter B,Wijermans PW,Lubbert M. DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients with myelodysplasia and acute myeloid leukemia. Int J Hematol. 2004; 80: 128135.
  • 43
    Issa JP,Garcia-Manero G,Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-Aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004; 103: 16351540.
  • 44
    Gryn J,Zeigler ZR,Shadduck RK, et al. Treatment of myelodysplastic syndromes with 5-azacytidine. Leuk Res. 2002; 26: 893897.
  • 45
    Silverman LR,Demakos EP,Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002; 20: 24292440.
  • 46
    Kuendgen A,Strupp C,Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood. 2004; 104: 12661269.
  • 47
    Ferrara FF,Fazi F,Bianchini A, et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res. 2001; 61: 27.
  • 48
    Phiel CJ,Zhang F,Huang EY, et al. Histone deacetylase is a direct target of valproid acid, a potent anticonvulsant, mood stabilizer and teratogen. J Biol Chem. 2001; 276: 3673436741.
  • 49
    Gottlicher M,Minucci S,Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001; 20: 69696978.